Comparing ziconotide and a drug combination to standard medical management for patients with severe cancer pain

3 1 1 1

What is this study about?

This study aims to compare the use of a drug delivery system through the spine with standard medical care for individuals experiencing Severe refractory cancer pain, which is intense pain caused by cancer that does not respond well to typical treatments. One group will receive a medical management approach using standard medications, while the other group will use an intrathecal drug delivery system, a method where medication is delivered directly into the fluid surrounding the spinal cord. The medications used in this study include ziconotide, ropivacaine hydrochloride, morphine hydrochloride, and bupivacaine hydrochloride.

Participants in the study involving the delivery system will receive these substances through a specialized pump. This approach involves intrathecal use, meaning the drugs are placed into the space between the membranes that cover the spinal cord to target pain more directly. During the course of the study, participants will be monitored to assess their quality of life, comfort levels, and how they manage the physical and emotional challenges of their condition.

Who Can Join the Study?

You must be an adult, which means you are 18 years of age or older.
You must have severe cancer pain that does not respond well to standard treatments, which is known as refractory pain.
You must have been taking opioids, which are strong medicines used to reduce pain, for at least 4 weeks.
You must be expected to continue taking opioids for the whole time you are in the study.
Before being included, you must have already tried changing your dose or type of opioid more than once, a process called opioid rotation.
You must be a candidate for intrathecal therapy, which is a way of delivering medicine directly into the fluid surrounding the spinal cord.
This therapy is recommended because your current systemic opioid treatment, which is medicine that travels through your entire body, is either not working well enough or is causing problems.
Your pain must be considered ineffective to treat, meaning your daily pain score on a scale of 0 to 100 is 50 or higher while resting.
Your treatment must be considered intolerable, meaning you have experienced adverse events, or harmful side effects, that prevent you from taking a higher dose of medicine to help with the pain.
You must be able to use an implanted drug delivery device (IDD), which is a small pump placed under the skin to provide medicine.
You must be able to follow the study rules and attend all scheduled medical appointments.
Doctors expect you to live for at least 3 months, which is known as your survival prognosis.

Who Cannot Join the Study?

Patients who currently have a serious or intense infection, which is when harmful germs like bacteria or viruses are actively making the body sick.
Patients who have brain metastases, which means cancer has spread from another part of the body to the brain.
Patients who have a high risk of hemorrhaging, which is the medical term for severe or uncontrolled bleeding.
Patients who have allergies, or harmful allergic reactions, to the medicines used in the study or to IDD hardware, which refers to medical devices implanted in the spine to treat disc problems.
Women who are currently pregnant or lactating, which means breastfeeding a baby.
Women who are planning to become pregnant within one month after the study ends.

Where you can join this trial?

Verified and Recommended Sites

No sites found in this category

Verified Sites

No sites found in this category

Other Sites

Site Name	City	Country	Status
Vrije Universiteit Brussel	Jette	Belgium

Trial status

Country	Status	Recruitment Start
Belgium	Not yet recruiting	22.01.2026

Trial locations

Investigated drugs:

Ziconotide is a medication administered directly into the fluid surrounding the spinal cord to help manage severe pain.

Ropivacaine is a local anesthetic used to provide pain relief by being injected into the spinal area to numb the nerves.

Morphine is a strong pain-relieving medication that is delivered into the spinal fluid to help manage intense pain.

Bupivacaine is a type of local anesthetic injected into the spinal area to block pain signals.

Investigated diseases:

Cancer pain

Severe refractory cancer pain – This condition involves intense physical discomfort caused by the presence of malignant tumors. It is characterized by pain that does not respond well to standard pain management approaches. As the underlying cancer progresses, the sensations typically become more persistent and difficult to manage. The discomfort may vary in intensity and can affect different parts of the body depending on the location of the cancer. Over time, the pain often becomes more continuous as the disease advances.

Trial ID:

2025-522381-68-00

Trial Phase:

Therapeutic confirmatory (Phase III)

Other Trials to Consider